8-KEarnings & ResultsExhibits & Filings

Merck & Co., Inc. 8-K Report, Financial Results (May 1, 2018)

Filed May 1, 2018For Securities:MRK

Summary

Merck & Co., Inc. (MRK) filed an 8-K on May 1, 2018, to report its financial results for the first quarter of 2018, which concluded on April 30, 2018. The filing primarily incorporates by reference a press release (Exhibit 99.1) detailing the company's performance and supplemental information (Exhibit 99.2) not found in the press release. This report provides investors with key financial data and operational updates for the initial quarter of the fiscal year. While the 8-K itself does not contain the detailed financial figures, it directs investors to the accompanying exhibits for a comprehensive understanding of Merck's Q1 2018 earnings. Investors should review Exhibits 99.1 and 99.2 to assess the company's revenue, profitability, and any significant business developments announced during the period. The filing also notes Merck's status as an emerging growth company but does not elect to use the extended transition period for new accounting standards.

Key Highlights

  • 1Merck & Co., Inc. (MRK) filed an 8-K on May 1, 2018, to announce Q1 2018 earnings.
  • 2The primary information is contained within the referenced press release (Exhibit 99.1).
  • 3Supplemental financial and operational data is provided in Exhibit 99.2.
  • 4The filing covers the financial performance and condition for the quarter ending April 30, 2018.
  • 5Merck is identified as an emerging growth company.
  • 6The company has opted not to use the extended transition period for new accounting standards.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly announce and provide access to Merck & Co., Inc.'s financial results and key updates for the first quarter of 2018, which ended on April 30, 2018. It incorporates by reference a press release and supplemental information for a detailed overview.

The specific financial results, including revenue, earnings, and other performance metrics for Q1 2018, are not directly in the 8-K filing itself. You need to refer to Exhibit 99.1 (the press release) and Exhibit 99.2 (supplemental information) that are attached to and incorporated by reference in this 8-K.

As an 'emerging growth company' (EGC), Merck is eligible for certain scaled-back disclosure and regulatory requirements under the JOBS Act. However, the filing indicates they have elected *not* to use the extended transition period for complying with new or revised financial accounting standards, meaning they are adhering to the same timeline as non-EGCs for adopting these standards.